david ettinger, md, on cost of therapy when choosing agents for late stage lung cancer patients
Published 8 years ago • 47 plays • Length 0:35
Download video MP4
Download video MP3
Similar videos
-
0:25
david ettinger, md, on choosing between immunotherapy and chemotherapy in metastatic nsclc patients
-
1:11
david ettinger, md, provides practical advice related to pd-l1 testing in metastatic nsclc patients
-
0:47
david ettinger, md, talks about levels of pd-l1 expression and agent selection
-
0:56
david ettinger, md, on the positioning of ramucirumab (cyramza) for nsclc
-
0:35
david ettinger, md, talks about impact of immunotherapy in 1st line metastatic nsclc patients
-
1:24
help for advanced lung cancer video
-
3:30
the cost-effectiveness of targeted therapies in nsclc
-
0:46
david gandara, md, discusses considerations when choosing between immunotherapy and chemotherapy
-
0:46
clinical trials in lung cancer explained video
-
1:06
david andorsky, md, discusses the implications of real-world evidence for oncologists
-
0:48
phil bonomi, md, discusses costs of new lung cancer therapies relative to duration of therapy
-
0:37
advise of a specilist - lung tumors
-
1:42
gene-based lung cancer treatment video
-
1:59
dr. herbst on key immunotherapy findings in nsclc
-
2:09
benefits of targeted therapeutics in lung cancer
-
6:15
lung cancer discussion with dr. joymon
-
1:47
dr. cheng discusses rictor amplification in lung cancer
-
2:09
jeremy abramson, md: a doctor’s perspective of car t-cell therapy | mass general brigham
-
1:47
nevena damjanov, md, discusses how new agents for advanced hcc will be integrated into the treatment
Clip.africa.com - Privacy-policy